Menglin Cheng1, Balaji Krishnamachary1, Zaver M. Bhujwalla1,2, Asif Rizwan1, Lu Jiang1, and Kristine Glunde1,2
1The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Glycerophosphocholine (GPC) is an important
MRS-detected metabolite in choline metabolism of breast cancer. Transient silencing
of the GPC-phosphodiesterases GDPD5 and GDPD6 increases 1H or 31P
MRS detectable GPC levels in breast cancer cells. Constitutive knockdown of
GDPD5 or GDPD6 effectively kills MCF-7 and MDA-MB-231 breast cancer cells, but
not nonmalignant MCF-12A breast epithelial cells, making GDPD5 and GDPD6
interesting theranostic targets whose knockdown or inhibition can be monitored
by non-invasive MRS.
